Anavex Life Sciences Corp (AVXL)

[TempePhil]

falconer good points. One more...
Will the caregiver get excited? Will the caregiver of a Lecanemab (or Lillys donanemab) patient, even be able to see the affect?

It is not like the patient will start driving again, or reading again, or playing piano again. These are A2-73 anecdotal patients.

Presumably, 27% is Lecanemab's average improvement over normal decline. Maybe the better responding patients actually have only a 50% decline with Lecanemab. Will the caregiver even be able to notice a better patient with a 50% reduction in decline? With dementia, it is easier to see an improvement(very rare!) than a modest change in rate of decline(without doing testing).

This is just a rhetorical question, tieing(sp?) your comments in with Mayos allusion to statistical vs clinical significance.